|Other Names||SOM230, SOM 230, UNII-98H1T17066|
|Trade Name||Orphan Drug|
|Effect Expectation||Brain Meningiomas|
|Inhibitor||Small Somatostatin (SST)|
|SST is a Growth Hormone (GH) Inhibited|
|IUPAC Name||[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate|
Treatment with Pasireotide, also known as SOM230, is meant to shrink brain Meningiomas tumor mass.
Many tumor suppressors for NF2 effect primarily brain Schwannoma tumors that are doing damage to different Cranial Nerves. However Meningiomas are issues as well.
Schwannoma tumors damage the nerves they grown on which is dangerous, but as Meningiomas grow larger, they are just as dangerous as they cause pressure on brain matter and result in different brain function issues. Issues developed would be based on the exact location and possibly size of each problematic tumor.
Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with
any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here,
the accuracy of other sites to which this site links, or of sites that link to this site. - Read More
Copyright © 2008 - 2017